Bicara Therapeutics Inc. ... (BCAX)
12.85
-0.14 (-1.08%)
At close: Jan 14, 2025, 3:59 PM
12.50
-2.72%
Pre-market Jan 15, 2025, 07:31 AM EST
undefined% (undefined)
| Bid | 12 |
| Market Cap | 699.24M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.09 |
| PE Ratio (ttm) | -11.79 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 17 |
| Volume | 419,000 |
| Avg. Volume (20D) | 418,363 |
| Open | 13.03 |
| Previous Close | 12.99 |
| Day's Range | 12.33 - 13.44 |
| 52-Week Range | 12.33 - 28.09 |
| Beta | undefined |
About BCAX
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 32
Stock Exchange NASDAQ
Ticker Symbol BCAX
Website https://www.bicara.com
Analyst Forecast
According to 5 analyst ratings, the average rating for BCAX stock is "Buy." The 12-month stock price forecast is $42, which is an increase of 226.85% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago ·
Source
+7.98%
Bicara Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
